Oncotype Dx (ODX) is a genetic assay that analyzes tumor recurrence risk and provides chemotherapy recommendations for T1-T2 stage, hormone receptor-positive, human epidermal growth factor receptor-negative, and nodal-negative breast cancer patients. Despite its established validity, the utilization of this assay is suboptimal. The study aims to evaluate factors that are associated with adherence rate with the testing guidelines and examine changes in utilization trends.
This is a retrospective study, utilizing data from the National Cancer Database from 2010 to 2017. Patients who met the ODX testing guidelines were first evaluated for testing adherence. Secondly, all patients who underwent ODX testing were assessed to evaluate the trend in ODX utilization.
A total of 429,648 patients met the criteria for ODX, and 43.4% of this population underwent testing. Advanced age, racial minorities, low-income status, well-differentiated tumor grade, uninsured status, and treatment at community cancer centers were associated with a decreased likelihood of receiving ODX in eligible patients. Additionally, a notable amount of testing was performed on patients who did not meet the ODX testing criteria. Among the 295,326 patients that underwent ODX testing, 16.6% of patients were node-positive and 1.8% had T3 or T4 stage tumors.
A considerable number of patients who were eligible for ODX did not receive it, indicating potential barriers to care and disparities in breast cancer treatment. ODX usage has been expanded to broader patient populations, indicating more research is needed to validate the effectiveness of the assay in these patient groups.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Surgical Research
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cancer treatment and survivorship statistics, 2016.CA: a Cancer J clinicians. 2016; 66: 271-289
- Effect of screening and adjuvant therapy on mortality from breast cancer.New Engl J Med. 2005; 353: 1784-1792
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet. 2005; 365: 1687-1717
- A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.New Engl J Med. 2004; 351: 2817-2826
- Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.New Engl J Med. 2018; 379: 111-121
- Breast Cancer Version 2. 2016 NCCN clinical practice guidelines in oncology. National Comprehensive Cancer Network (NCCN). 2016 (Plymouth Meeting, PA)
- Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor–positive breast cancer.J Clin Oncol. 2006; 24: 3726-3734
- Disparities in compliance with the oncotype DX breast cancer test in the United States: a national cancer data base assessment.Am J Surg. 2018; 215: 686-692
- Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.Breast Cancer Res Treat. 2015; 151: 149-156
- Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.J Clin Oncol. 2010; 28: 1829-1834
- Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.Breast Cancer Res Treat. 2017; 163: 303-310
- Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer.Lab Invest. 2014; 94: 98-106
- 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.New Engl J Med. 2021; 385: 2336-2347
- Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004–2015.Breast Cancer Res Treat. 2020; 180: 491-501
- 21-gene recurrence scores: racial differences in testing, scores, treatment, and outcome.Cancer. 2012; 118: 788-796
- Parity and disparity in first course treatment of invasive breast cancer.Breast Cancer Res Treat. 2008; 109: 545-557
- Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.Breast Cancer Res Treat. 2018; 168: 207-220
- “Oncotype DX Tests.” breastcancer.org.(Available at:)www.breastcancer.org/screening-testing/oncotype-dxDate accessed: November 1, 2021
- Utilization of Oncotype DX in an inner city population: race or place?.Int J Breast Cancer. 2013;
- Place as a predictor of health insurance coverage: a multivariate analysis of counties in the United States.Health Place. 2015; 34: 207-214
- Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis.Breast Cancer Res Treat. 2015; 152: 611-625
- Prospective clinical utility study of the use of the 21-gene assay in adjuvant clinical decision making in women with estrogen receptor-positive early invasive breast cancer: results from the SWITCH study.The Oncologist. 2015; 20: 873-879
- Prospective evaluation of the 21-gene recurrence score assay for breast cancer decision-making in Ontario.J Clin Oncol. 2016; 34: 1065-1071
- Prognostic utility of the 21-gene assay in hormone receptor–positive operable breast cancer compared with classical clinicopathologic features.J Clin Oncol. 2008; 26: 4063
- A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.J Natl Cancer Inst. 2013; 105: 701-710
Published online: February 07, 2023
Accepted: January 8, 2023
Received in revised form: December 11, 2022
Received: February 28, 2022
© 2023 Elsevier Inc. All rights reserved.